Clinical Trials Update: Mar. 17, 2003
Lung Cancer Allergy (Pediatric) Breast Cancer
(HealthDayNews) -- Here are the latest clinical trials, courtesy of CenterWatch:Clinical Trials Update: Mar. 17, 2003
A research study of a peptide vaccine in patients with stage IIb or IIIa non-small cell lung cancer (NSCLC). Patients who have confirmed NSCLC staged as IIb or IIIa, have no evidence of disease (NED) after their standard treatment, and who meet certain inclusion and exclusion criteria are eligible. Research sites located throughout the United States.
A research study to determine the rate at which a FDA approved allergy medication is metabolized in children ages 2-11. Children who suffer or have suffered from allergies, asthma, or certain skin conditions or have used antihistamines may qualify to participate. Research site located in Baltimore, Maryland.
A research study to examine the ability of the study drug to change the rate of cell growth as well as expression of proteins associated with breast cancer. Volunteers must be females at least 18 years of age and diagnosed with certain types of breast cancer as a result of a biopsy. Research site located in Kansas City, Kansas.
Copyright 2003 CenterWatch. All rights reserved.